In a report released today, Derik De Bruin from Merrill Lynch maintained a Hold rating on Qiagen NV (QGEN), with a price target of $33.00. The company’s shares closed last Monday at $25.58, close to its 52-week low of $25.13.
According to TipRanks.com, Bruin is a 4-star analyst with an average return of 5.1% and a 56.6% success rate. Bruin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Inc., Guardant Health Inc, and IQVIA Holdings Inc.
Qiagen NV has an analyst consensus of Hold, with a price target consensus of $31.87, a 22.4% upside from current levels. In a report released today, Barclays also downgraded the stock to Hold with a $32.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41.55 and a one-year low of $25.13. Currently, Qiagen NV has an average volume of 817.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services.
